• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian red crescent medical journal >The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial
【24h】

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

机译：益生菌和/或益生元对非酒精性脂肪肝患者肝功能检查的影响：双盲随机临床试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Oral administration of pro- and prebiotics has recently been considered as an effective way for nonalcoholic fatty liver disease (NAFLD) recovery. Objectives: The current study aimed at evaluating the effect of supplementation with probiotics and/or prebiotics on liver function tests in patients with NAFLD. Methods: In this double blind, placebo-control clinical trial, 75 subjects with NAFLD were voluntarily recruited from May 2013 to March 2014, in Iran. Participants were randomly assigned to 1 of 4 groups using a block randomization procedure. Group 1 received probiotic capsules (Bifidobacterium longum (BL) and Lactobacillus acidophilus (LA): 2 × 107 CFU/day), group 2 received prebiotic inulin high performance (HP): 10 g/day, group 3 received probiotic and the prebiotic, and group 4 received a placebo for 3 months. The sample size was determined on the basis of a primary outcome of a change in aspartate aminotransferase (AST) level. Results: An intergroup comparison indicated that the AST (P = 0.006) and alanine aminotransferase (ALT) (P = 0.04) levels decreased at the end of the study. Aspartate Aminotransferase (mean difference of group1 versus placebo with P value of 0.001, group2 versus placebo with P value of 0.045, group3 versus placebo with P value of 0.015) and ALT (mean difference of group 1 versus placebo with P value of 0.009, group 2 versus placebo with P value of 0.041, and group 3 versus placebo with P value of 0.046) serum levels decreased significantly in all of the intervention groups compared to the placebo. The grade of fatty liver in group 1 (P of 0.027, and number needed to treat (NNT) = 3) and group 3 (P = 0.019 and NNT = 3) decreased compared to the placebo group with no significant changes in group 2. Conclusions: Supplementation wit
机译：背景：益生元和益生元的口服给药最近被认为是恢复非酒精性脂肪肝疾病（NAFLD）的有效方法。目的：本研究旨在评估补充益生菌和/或益生元对NAFLD患者肝功能测试的影响。方法：在这项双盲，安慰剂对照临床试验中，从2013年5月至2014年3月在伊朗自愿招募了75名NAFLD受试者。使用区组随机程序将参与者随机分配到4组中的1组。第1组接受益生菌胶囊（长双歧杆菌（BL）和嗜酸乳杆菌（LA）：2×107 CFU /天），第2组接受高效益生菌菊粉（HP）：10 g /天，第3组接受益生菌和益生菌，第4组接受安慰剂治疗3个月。样品量是根据天冬氨酸转氨酶（AST）水平变化的主要结果确定的。结果：组间比较表明，研究结束时AST（P = 0.006）和丙氨酸转氨酶（ALT）（P = 0.04）水平降低。天冬氨酸转氨酶（第1组与安慰剂的平均差异P值为0.001，第2组与安慰剂的P值为0.045，第3组相对于安慰剂的P值为0.015）和ALT（第1组与安慰剂的平均差异P值为0.009，组）与安慰剂相比，在所有干预组中，第2组与安慰剂的P值为0.041，第3组与安慰剂的P值为0.046）。与安慰剂组相比，第1组的脂肪肝等级（P = 0.027，需要治疗的数量（NNT）= 3）和第3组（P = 0.019和NNT = 3）降低，而第2组无明显变化。结论：补充机智

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号